NCT05204758View on ClinicalTrials.gov

Prophylactic TCM for Mitigation of EGFR-TKI Related Dermatological Adverse Effect

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 12, 2016

Primary Completion Date

December 31, 2017

Study Completion Date

February 28, 2021

Conditions
Advanced Lung Adenocarcinoma
Interventions
DRUG

TCM Formula

three packages of TCM preparations with each meal three times a day

DRUG

Placebo

three packages of placebo preparations with each meal three times a day

All Listed Sponsors
lead

China Medical University Hospital

OTHER

NCT05204758 - Prophylactic TCM for Mitigation of EGFR-TKI Related Dermatological Adverse Effect | Biotech Hunter | Biotech Hunter